Related Experiment Videos
Activated tissue renin-angiotensin systems add to the progression of heart failure
Y M Pinto1, H Buikema, W H van Gilst
1Dept. of Cardiology, University of Groningen, The Netherlands.
Insights
Activated tissue renin-angiotensin systems may harm heart failure. Inhibiting these systems could be key, but more human studies are needed to confirm this for heart failure treatment.
Area of Science:
- Cardiovascular Science
- Renal Physiology
- Pharmacology
Background:
- Heart failure is a complex condition with significant morbidity and mortality.
- The renin-angiotensin system (RAS) is a key regulator of blood pressure and fluid balance.
- Dysregulation of the RAS is implicated in the progression of heart failure.
Purpose of the Study:
- To review the hypothesis that activated tissue renin-angiotensin systems (tRAS) contribute to heart failure.
- To discuss the evidence supporting the distinct function and activation of tRAS in heart failure.
- To explore the therapeutic implications of inhibiting tRAS for heart failure management.
Main Methods:
- Literature review and synthesis of existing research.
- Analysis of studies investigating tissue-specific RAS components.
- Examination of evidence linking tRAS activation to cardiovascular dysfunction.
Main Results:
- Tissue RAS function differs from circulating RAS.
- Evidence suggests tRAS activation in heart failure.
- Activated tRAS is linked to detrimental cardiovascular effects.
Conclusions:
- The hypothesis posits that activated tRAS plays a detrimental role in heart failure.
- Inhibition of tRAS may represent a novel therapeutic strategy.
- Further research, especially in human subjects, is required to validate this prediction.
Abstract:
In this paper, we review the hypothesis that activated tissue renin-angiotensin systems play a detrimental role in heart failure. The main arguments for this idea are discussed: a) tissue renin-angiotensin systems behave functionally distinct from the circulating renin-angiotensin system; b) tissue renin-angiotensin systems are activated in heart failure; c) activated tissue renin-angiotensin systems induce cardiovascular dysfunction. Finally, this hypothesis predicts that optimal treatment in heart failure requires the inhibition of tissue renin-angiotensin systems. However, studies pertaining to this prediction are still lacking, particularly in human subjects.